Literature DB >> 16574512

Simple and rapid liquid chromatography method for determination of efavirenz in plasma.

Geetha Ramachandran1, A K Hemanth Kumar, Soumya Swaminathan, P Venkatesan, V Kumaraswami, David J Greenblatt.   

Abstract

A simple and rapid high performance liquid chromatographic method for determination of efavirenz in human plasma was developed. The method involved extraction of sample with ethyl acetate and analysis using a reversed-phase C(18) column (150 mm) with UV detection. The assay was linear from 0.0625 to 10.0 microg/ml. The method was specific for efavirenz estimation and the drug was stable in plasma up to one month at -20 degrees C. The average recovery of efavirenz from plasma was 101%. Due to its simplicity, the assay can be used for pharmacokinetic studies and therapeutic drug monitoring of efavirenz.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16574512     DOI： 10.1016/j.jchromb.2006.03.014

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.205


  9 in total

1.  A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma.

Authors:  Lindsay B Avery; Teresa L Parsons; David J Meyers; Walter C Hubbard
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-10-08       Impact factor: 3.205

2.  Study of ABCB1 polymorphism (C3435T) in HIV-1-infected individuals from South India.

Authors:  Siddharth Bakshi; Geetha Ramachandran; Karunaianandham Ramesh; Agibothu K Hemanthkumar; Suresh Anitha; Chandrasekaran Padmapriyadarsini; Gopalan Narendran; Pradeep A Menon; Sikhamani Rajasekaran; Soumya Swaminathan
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

3.  CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; Sikhamani Rajasekaran; P Kumar; K Ramesh; S Anitha; G Narendran; Pradeep Menon; C Gomathi; Soumya Swaminathan
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

4.  Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W Sagoe; Fafa Xexemeku; Ernest Kenu; Joseph Oliver-Commey; Vincent Boima; Augustine Sagoe; Isaac Boamah; David J Greenblatt; Michael H Court
Journal:  J Clin Pharmacol       Date:  2008-09       Impact factor: 3.126

5.  Development and validation of reversed-phase HPLC gradient method for the estimation of efavirenz in plasma.

Authors:  Shweta Gupta; Rajesh Kesarla; Narendra Chotai; Abdelwahab Omri
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

6.  A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.

Authors:  Praveen Srivastava; Ganesh S Moorthy; Robert Gross; Jeffrey S Barrett
Journal:  PLoS One       Date:  2013-06-05       Impact factor: 3.240

7.  Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy.

Authors:  Kuan-Yin Lin; Sih-Han Liao; Wen-Chun Liu; Aristine Cheng; Shu-Wen Lin; Sui-Yuan Chang; Mao-Song Tsai; Ching-Hua Kuo; Mon-Ro Wu; Hsiu-Po Wang; Chien-Ching Hung; Shan-Chwen Chang
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

8.  Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.

Authors:  Kuan-Yeh Lee; Shu-Wen Lin; Hsin-Yun Sun; Ching-Hua Kuo; Mao-Song Tsai; Bing-Ru Wu; Sue-Yo Tang; Wen-Chun Liu; Sui-Yuan Chang; Chien-Ching Hung
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

9.  Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.

Authors:  Geetha Ramachandran; A K Hemanth Kumar; C Ponnuraja; K Ramesh; Lakshmi Rajesh; C Chandrasekharan; Soumya Swaminathan
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.